
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

BIO Services

08 March 2010 | News



SIRO forms alliance with Korean CRO

SIRO Clinpharm, a contract research organization (CRO) with presence in India, Europe, and the US has formed an alliance with DreamCIS, a leading CRO based in Seoul, South Korea.

DreamCIS offers clinical research services to pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers.
Â
Ã¢â?¬Å?We are one of the leading CROs in South Korea. However, considering increasing number of global clinical trials and the rapid growth in Asian clinical trials market, we were looking at associating with a CRO having a global exposure; not only from business perspective but also from the perspective of moving up on the learning curve. I think our mutually beneficial alliance with SIRO is a definite step in this direction,Ã¢â?¬? said Won-Jung Choi, president, DreamCIS.

Ã¢â?¬Å?Korea is a rapidly growing clinical trials market due to pre-approved and well-equipped clinical trial sites, trained professionals, and transparent and efficient regulatory processes. We are confident that this alliance will be of immense value addition to SIRO and widen our global service capabilities,Ã¢â?¬? said Dr Chetan Tamhankar, CEO, SIRO Clinpharm.

Endo, Jubilant expand oncology partnership

Jubilant Biosys and Endo Pharmaceuticals have expanded their drug discovery partnership in oncology. This one-year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered as part of the partnership. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development, Sri Mosur, CEO and president, Global Drug Discovery and Development, Jubilant Biosys, said, Ã¢â?¬Å?We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant's focus on building world-class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide.Ã¢â?¬?

Omnicare licenses LiquentConnect SaaS solution

Omnicare Clinical Research has licensed LiquentConnect, a hosted software as a service (SaaS) solution used to create, review, amend and submit regulatory dossiers. Omnicare Clinical Research is a phase I to IV global contract research organization serving the biopharmaceutical and medical device industries.

LiquentConnect enables organizations to produce their own eCTD and non-electronic submissions without investing in IT infrastructure. All software and hardware upgrades are managed and executed by Liquent, a regulatory and clinical services provider for the life sciences industry. LiquentConnect is fully-executable for eCTD, NeeS and CTD publishing.

Omnicare Clinical Research selected Liquent and will be utilizing LiquentConnect as its hosted solution provider due to its depth of expertise within the regulatory and life sciences industry. The benefits of implementing a fully-managed SaaS solution outweighed the time and resource investment required for other solutions.

ClinTec's sales revenue up by 45%

ClinTec International, a full-service CRO, has achieved organic growth with a 45 percent increase in global sales revenues over the last 12 months. The company has also expanded its client base and signed new contracts with 11 of the world's top 25 pharmaceutical firms.

ClinTec has played a key role in 2009 in facilitating complex restructuring programs for global pharma, who are searching for innovative ways to optimize their R&D efforts.

Kemwell builds new facility in Bangalore

Bangalore-based CRAMS player, Kemwell has started the construction works of its new non-sterile liquid facility in Bangalore. The new facility will be ready for operation in May 2011, and it will double Kemwell's current capacity to produce 250 million bottles per year, with provisions to increase the capacity to another 60 million bottles annually. The facility will be highly automated and flexible to serve both large and small scale requirements of Kemwell's current and new customers. It will also be designed to meet the quality requirements of regulated markets.

Clinigene deploys SAS software solution

Clinigene, a Biocon group company and a full-service CRO has deployed SAS Clinical Data Management -PheedIt solution to accelerate its clinical research.

Manoj Yasodharan, manager - clinical data management and biostatistics, Clinigene International, said, Ã¢â?¬Å?SAS PheedIt provides a complete solution for clinical data management and analysis. We have successfully reduced the time to setup new trial projects. SAS partnership gives control over the entire data management, analysis and reporting process.Ã¢â?¬?